With a $163,356 grant from FRAXA Research Foundation in 2010-12, Dr. Scott Soderling and Dr. Hwan Kim at Duke University bred the standard mouse model of Fragile X syndrome to their lines of mice that express reduced levels of several key proteins that modulate synaptic actin. These compound mutant mice were compared to FXS mice to determine if genetically impairing pathways to the actin cytoskeleton can rescue deficits in the FXS mice.
Read moremGluR
Compound that Inhibits mGluR5 Corrects Signs of Fragile X in Adult Mice
A study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS). The paper is published in the April 12 issue of the journal Neuron, describing the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established. Previous research has suggested that inhibition of mGlu5, a subtype of receptor for the excitatory neurotransmitter glutamate, may ameliorate many of the major symptoms of the disease. This study, a collaboration between a group at Roche in Switzerland, led by Dr. Lothar Lindemann, and Dr. Mark Bear’s MIT lab, used an mGlu5 inhibitor called CTEP to examine whether inhibition of mGlu5 could reverse FXS symptoms.
Read moreRole of JNK in FMRP Regulated Translation in Fragile X Syndrome
![Role of JNK in FMRP Regulated Translation in Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2013/06/Wilhelm.jpg)
With a $90,000 grant from FRAXA Research Foundation over 2 years, Dr. Michael Wilhelm and his team at the University of Wisconsin studied a protein known as JNK, which is observed to be abnormally regulated in Fragile X. Like FMRP, it is involved in regulating dendritic protein synthesis, and so it may be a target for drug therapy in Fragile X.
Read moreRole of Excessive Protein Synthesis in the Ontogeny of FXS
![Role of Excessive Protein Synthesis in the Ontogeny of FXS](https://www.fraxa.org/wp-content/uploads/2013/05/mark-bear-1-e1525888546663-720x300.jpg)
With a $90,000 grant from FRAXA Research Foundation in 2010-2011, Dr. Mark Bear and Dr. Miquel Bosch tested the simple hypothesis that the excessive rate of protein synthesis is not a consequence but the primary cause of the structural alterations occurring in Fragile X syndrome.
Read moreManipulating Basal and mGluR-Stimulated cAMP Level in FXS Model Mice
![Manipulating Basal and mGluR-Stimulated cAMP Level in FXS Model Mice](https://www.fraxa.org/wp-content/uploads/2013/07/hongbingwang_wang.jpg)
With a $90,000 grant from FRAXA Research Foundation, Dr. Hongbing Wang’s team from Michigan State University looked at a treatment target “downstream” of the mGluR5 called cyclic AMP (cAMP). Levels of cAMP are lower in FXS patients and animal models, suggesting that it plays a role in FXS. Drugs that raise levels of cAMP may effectively treat Fragile X. We are very pleased to report that, in 2012, Dr. Wang received a 5-year, $250,000 per year R01 grant from NIH to continue this promising research.
Read moreThe Role of FMRP and Small, Non-Coding RNAs in Translation
![The Role of FMRP and Small, Non-Coding RNAs in Translation](https://www.fraxa.org/wp-content/uploads/2018/01/Tiedge-Photo.jpg)
With a $120,000 grant from FRAXA Research Foundation, Drs. Henri Tiedge and Jun Zhong studied the mechanisms by which local protein translation is repressed. Multiple parallel mechanisms keep protein synthesis in check; one of them involves FMRP, and a similar mechanism involves the non-coding RNA, BC1. Results published.
Read moreDeveloping Fragile X Treatments in Fruit Flies and Mice
![Developing Fragile X Treatments in Fruit Flies and Mice Sean McBride, PhD, Albert Einstein College of Medicine, FRAZA research grant](https://www.fraxa.org/wp-content/uploads/2009/07/mcbride-sean.jpg)
With a $380,000 grant from FRAXA Research Foundation from 2005-2009, Drs. Sean McBride, Tom Jogens, and Catherine Choi studied one of the most important aspects of FRAXA’s research; the preclinical validation of potential therapeutic strategies. Many labs have found new leads for treatment. However, very few have the capacity to test new drugs in the mouse model to establish efficacy rigorously enough to lead to clinical trials. The McBride lab (in a broad collaboration with the Choi, Jongens, and Skoulakis groups) aims to do just that. Results published.
Read moreImaging Synaptic Structure and Function in Fragile X Mice
![Imaging Synaptic Structure and Function in Fragile X Mice](https://www.fraxa.org/wp-content/uploads/2009/07/Carlos-Cailliau.jpg)
FRAXA Research Foundation grants $150,000 over 2005-2009 to Dr. Carlos Portera-Cailliau to study intact, anesthetized Fragile X mouse brains, looking for defects in the density, length, or dynamics of the dendrites. They looked for changes in the neurons after treatment with mGluR5 antagonists.
Read moreRole of Matrix Metalloproteinases (MMP-9) in Fragile X
![Role of Matrix Metalloproteinases (MMP-9) in Fragile X Iryna Ethell, PhD, at University of California](https://www.fraxa.org/wp-content/uploads/2013/05/ethell.jpg)
With a $220,000 grant from FRAXA Research Foundation over 3 years, Dr. Iryna Ethell from the University of California at Riverside studied the regulation of dendritic structure by matrix metalloproteinases and other extracellular signaling pathways. This work identified a major treatment strategy for Fragile X with the available MMP-9 inhibitor, minocycline.
Read moreBasic Mechanisms of Disease and Potential Therapeutic Strategies
![Basic Mechanisms of Disease and Potential Therapeutic Strategies](https://www.fraxa.org/wp-content/uploads/2018/01/steve_warren_hires-720x300.jpg)
With $245,000 in grants from FRAXA Research Foundation, Dr. Stephen Warren and his lab at Emory University studied all aspects of Fragile X syndrome, from the mechanisms of repeat expansion to high-throughput drug screens in the Drosophila model of Fragile X. The Warren lab made the original discovery of the Fragile X gene, FMR1, in collaboration with the Nelson and Oostra labs, and is recognized internationally as a leader in molecular genetics. Recent projects include establishment of induced pluripotent stem cell lines from Fragile X patients, and determination of other forms of mutation in the Fragile X gene, other than the most common trinucleotide repeat expansion.
Read moreRole of FMRP in the Regulation of Synaptic Plasticity
![Role of FMRP in the Regulation of Synaptic Plasticity](https://www.fraxa.org/wp-content/uploads/2018/01/william-greenough-700x300.jpg)
With more than $1,000,000 from FRAXA Research Foundation over 13 years, Drs. William Greenough and Ivan-Jeanne Weiler at the University of Illinois uncovered the role of FMRP at synapses, leading to much of the subsequent research on Fragile X syndrome.
Read moreGlutamate Metabolism in Fragile X Mouse Brain
![Glutamate Metabolism in Fragile X Mouse Brain](https://www.fraxa.org/wp-content/uploads/2018/02/McKenna_Mary-400x300.jpg)
With a $95,000 grant from FRAXA Research Foundation over 2 years, Mary McKenna at the University of Maryland studied the role of metabotropic glutamate receptors (mGluR) and how they affect other cells and pathways.
Read moreTargeting the Role of Group 1 Metabotropic Glutamate Receptors
![Targeting the Role of Group 1 Metabotropic Glutamate Receptors](https://www.fraxa.org/wp-content/uploads/2018/02/s200_huibert.mansvelder.jpg)
With a $40,000 grant from FRAXA Research Foundation in 2008, Dr. Huibert Mansvelder and his team at the University of Amsterdam studied the role of different receptors and their reactions to drug compounds.
Read moreDecreased Excitatory Drive onto Parvalbumin-Positive Neocortical Inhibitory Neurons in a Mouse Model of Fragile X Syndrome
![Decreased Excitatory Drive onto Parvalbumin-Positive Neocortical Inhibitory Neurons in a Mouse Model of Fragile X Syndrome Jay Gibson, PhD, at University of Texas at Southwestern, FRAXA research grant](https://www.fraxa.org/wp-content/uploads/2006/07/gibson-jay.jpg)
With an $80,000 grant from FRAXA Research Foundation over 2006-7, Drs. Jay Gibson and Kimberly Huber at the University of Texas at Southwestern examined if the defected inhibitory neurotransmission was a primary or secondary symptom of Fragile X to determine where future treatment targets should be focused.
Read moreElectrophysiological, Biochemical and Immunohistochemical Characterization of Kv3.1 in Auditory Brainstem Nuclei in the Fragile X Knockout Mouse
![Electrophysiological, Biochemical and Immunohistochemical Characterization of Kv3.1 in Auditory Brainstem Nuclei in the Fragile X Knockout Mouse Leonard Kaczmarek, PhD](https://www.fraxa.org/wp-content/uploads/2013/06/KaczmarekLeonardK.jpg)
With $80,000 in funding from FRAXA over several years, the Yale University team of Leonard Kaczmarek, PhD showed that loss of FMRP leads to an increased Kv3.1 potassium currents. This change impairs timing of action potentials in auditory neurons (and likely others throughout the brain).
Read moreMetabotropic Glutamate Receptor Function in Fragile X Knockout Mice
![Metabotropic Glutamate Receptor Function in Fragile X Knockout Mice Walter Kaufman, MD, PhD, at Johns Hopkins University, FRAXA research grant](https://www.fraxa.org/wp-content/uploads/2006/03/kaufman-walter.jpg)
With $143,000 in grants from FRAXA Research Foundation from 2004-2006, Drs. Walter Kaufmann, Richard Huganier, Paul Worley, and David Lieberman at Johns Hopkins University studied the molecular dynamics of mGluRs in areas involved in cognition in the Fragile X knockout mouse.
Read morePharmacologic Interventions in the Fmr1 KO Mouse
![Pharmacologic Interventions in the Fmr1 KO Mouse Catherine Choi, Drexel University, FRAXA research grant](https://www.fraxa.org/wp-content/uploads/2006/01/choi-catherine.jpg)
With $48,600 in grants from FRAXA Research Foundation over 2004-2006, Dr. Catherine Choi at Drexel University studied Fragile X knockout mice to determine future treatment targets for Fragile X syndrome in humans.
Read moreTransport, Anchoring and Translation of FMRP-Associated mRNAs
![Transport, Anchoring and Translation of FMRP-Associated mRNAs Vladimir Gelfand, PhD, at Northwestern University, FRAXA research grant](https://www.fraxa.org/wp-content/uploads/2005/07/gelfand-vladmir-200x300.jpg)
With a $40,000 grant from FRAXA Research Foundation in 2005, Dr. Vladimir Gelfand and his team at Northwestern University studied the mechanisms of mGluR and mRNA and how it relates to FMRP.
Read moreTreatment of a Mouse Model of Fragile X Syndrome with MPEP
![Treatment of a Mouse Model of Fragile X Syndrome with MPEP Linda Crnic, PhD, at University of Colorado, FRAXA research grant](https://www.fraxa.org/wp-content/uploads/2003/01/crnic-linda.jpg)
With a $49,000 grant from FRAXA Research Foundation in 2003, Dr. Linda Crnic at the University of Colorado continued studies of MPEP in Fragile X mice, exploring whether chronic use improves symptoms of Fragile X syndrome without impairing cognitive function.
Read moreSynaptic Plasticity and Olfactory Learning in Fragile X
![Synaptic Plasticity and Olfactory Learning in Fragile X](https://www.fraxa.org/wp-content/uploads/2000/02/Larson-Photo-300x200.jpg)
With a $40,000 grant from FRAXA Research Foundation in 2000, Dr. John Larson and his team at the University of Illinois Chicago used olfaction (sense of smell) in mice as a neuro-behavioral model system for human memory. They characterized olfactory sensitivity, learning, and memory in FMR1 knockout mice as compared to wild-type (normal control) mice.
Read more